SI2175875T1 - Sestavki iz prokariontske fenilalanin amonij-liaze in metode za zdravljenje raka z uporabo le-teh sestavkov - Google Patents

Sestavki iz prokariontske fenilalanin amonij-liaze in metode za zdravljenje raka z uporabo le-teh sestavkov

Info

Publication number
SI2175875T1
SI2175875T1 SI200831703A SI200831703A SI2175875T1 SI 2175875 T1 SI2175875 T1 SI 2175875T1 SI 200831703 A SI200831703 A SI 200831703A SI 200831703 A SI200831703 A SI 200831703A SI 2175875 T1 SI2175875 T1 SI 2175875T1
Authority
SI
Slovenia
Prior art keywords
compositions
lyase
methods
treating cancer
phenylalanine ammonia
Prior art date
Application number
SI200831703A
Other languages
English (en)
Slovenian (sl)
Inventor
Michel C. Vellard
Paul A. Fitzpatrick
Emil D. Kakkis
Daniel J. Wendt
Mubarack Muthalif
Sean M. Bell
Augustus O. Okhamafe
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40363135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2175875(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of SI2175875T1 publication Critical patent/SI2175875T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200831703A 2007-08-17 2008-08-15 Sestavki iz prokariontske fenilalanin amonij-liaze in metode za zdravljenje raka z uporabo le-teh sestavkov SI2175875T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6612507P 2007-08-17 2007-08-17
PCT/US2008/009765 WO2009025760A2 (en) 2007-08-17 2008-08-15 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
EP08795357.6A EP2175875B1 (en) 2007-08-17 2008-08-15 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Publications (1)

Publication Number Publication Date
SI2175875T1 true SI2175875T1 (sl) 2017-01-31

Family

ID=40363135

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831703A SI2175875T1 (sl) 2007-08-17 2008-08-15 Sestavki iz prokariontske fenilalanin amonij-liaze in metode za zdravljenje raka z uporabo le-teh sestavkov

Country Status (23)

Country Link
US (4) US7537923B2 (enExample)
EP (1) EP2175875B1 (enExample)
JP (1) JP5584120B2 (enExample)
CN (1) CN101803492B (enExample)
AR (2) AR067972A1 (enExample)
AU (1) AU2008289549B2 (enExample)
BR (2) BR122018072594B8 (enExample)
CA (1) CA2687028C (enExample)
CL (1) CL2008002390A1 (enExample)
CY (1) CY1118222T1 (enExample)
DK (1) DK2175875T3 (enExample)
ES (1) ES2602618T3 (enExample)
HR (1) HRP20161474T1 (enExample)
HU (1) HUE029510T4 (enExample)
LT (1) LT2175875T (enExample)
MX (1) MX2009012261A (enExample)
PE (1) PE20090605A1 (enExample)
PL (1) PL2175875T3 (enExample)
PT (1) PT2175875T (enExample)
RU (2) RU2009141987A (enExample)
SI (1) SI2175875T1 (enExample)
TW (1) TWI418787B (enExample)
WO (1) WO2009025760A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
EP3381445B1 (en) * 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
US20110201022A1 (en) * 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
WO2011078667A2 (en) 2009-12-22 2011-06-30 Dsm Ip Assets B.V. Method of finding a biocatalyst having ammonia lyase activity
EP2531209B1 (en) 2010-02-04 2016-04-20 BioMarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
CA2880620A1 (en) * 2012-07-27 2014-01-30 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
SG11201508598YA (en) * 2013-04-18 2015-11-27 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
WO2015153102A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
DK3145536T3 (da) 2014-04-16 2022-01-03 Codexis Inc Modificeret tyrosinammoniaklyase
ES2897635T3 (es) 2014-04-29 2022-03-02 Bio Cancer Treat International Ltd Métodos y composiciones para modular el sistema inmunológico con la arginasa I
WO2016008886A1 (en) 2014-07-14 2016-01-21 Danmarks Tekniske Universitet Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity
KR102438885B1 (ko) 2014-12-22 2022-09-01 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
IL263801B2 (en) 2016-07-26 2024-01-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
IT201600086488A1 (it) * 2016-08-22 2018-02-22 St Microelectronics Srl Dispositivo a semiconduttore e corrispondente procedimento
NZ755628A (en) * 2017-02-13 2023-09-29 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
WO2019217513A2 (en) 2018-05-09 2019-11-14 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US10900055B2 (en) 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
US11473077B2 (en) 2018-12-14 2022-10-18 Codexis, Inc. Engineered tyrosine ammonia lyase
CN113544268A (zh) 2018-12-20 2021-10-22 科德克希思公司 人类α半乳糖苷酶变体
KR102884442B1 (ko) 2019-02-14 2025-11-10 솜 이노베이션 바이오테크, 에스.에이. 페닐케톤뇨증 치료에 사용하기 위한 트리암테렌 또는 놀라트렉세드
US20220288208A1 (en) * 2019-08-07 2022-09-15 Rakuten Medical, Inc. Cetuximab-ir700 conjugate compositions
US11987823B2 (en) 2019-08-30 2024-05-21 Societe Des Produits Nestle S.A. Engineered lipase variants
WO2021127457A1 (en) 2019-12-20 2021-06-24 Codexis, Inc. Engineered acid alpha-glucosidase variants
CA3168922A1 (en) 2020-02-04 2021-08-12 Codexis, Inc. Engineered leucine decarboxylases
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用ａａｖ及治療調配物之苯酮尿症治療
JP2023539632A (ja) 2020-08-28 2023-09-15 コデクシス， インコーポレイテッド 操作されたプロテアーゼバリアント
MX2023002421A (es) 2020-08-28 2023-05-18 Codexis Inc Variantes de amilasa modificadas geneticamente.
US11918633B2 (en) 2021-05-19 2024-03-05 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
AU2022279241A1 (en) 2021-05-21 2023-11-30 Codexis, Inc. Engineered methionine gamma lyase variants
CN115873837A (zh) * 2022-11-18 2023-03-31 安徽盈科生物科技有限公司 高表达的新型的苯丙氨酸解氨酶
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
US20250161466A1 (en) 2023-11-17 2025-05-22 Biomarin Pharmaceutical Inc. Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5212939A (en) * 1991-12-04 1993-05-25 Pratt Jr John M Marine mooring swivel fitting
PT668933E (pt) * 1992-11-19 2003-02-28 Anticancer Inc Utilizacao de metioninase como agente anti-tumor em qimioterapia anti-metionina
ATE361984T1 (de) 1992-12-04 2007-06-15 Me Medical Enzymes Ag Gentechnologisch hergestellte glutaminase und ihre verwendung in therapie
DK75593D0 (enExample) 1993-06-25 1993-06-25 Novo Nordisk As
KR0164757B1 (ko) * 1995-06-13 1999-01-15 김광호 공조장치의 살균집진장치와 그 방법
DE851925T1 (de) * 1995-09-21 2003-08-14 Genentech Inc., San Francisco Varianten des menschlichen wachstumshormons
CU22585A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) * 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) * 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) * 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
CA2328614C (en) 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001257032A1 (en) * 2000-04-14 2001-10-30 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6967097B2 (en) 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
US6939941B2 (en) * 2001-09-12 2005-09-06 Toray Fine Chemicals Co., Ltd. Preparation of polysulfide compositions
WO2003072743A2 (en) 2002-02-26 2003-09-04 E.I. Du Pont De Nemours And Company Method for the recombination of genetic elements
EP1576127A4 (en) 2002-11-14 2006-10-25 Scripps Research Inst CRYSTAL FORM OF FATTY ACID AMINE HYDROLASE (FAAH)
US7553653B2 (en) 2004-09-17 2009-06-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP1869174B1 (en) * 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
DE102006032167B4 (de) 2006-07-12 2014-11-27 Evonik Degussa Gmbh Verfahren zur Herstellung von Triallylisocyanurat (TAIC)
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US20110201022A1 (en) 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase

Also Published As

Publication number Publication date
AU2008289549A1 (en) 2009-02-26
TWI418787B (zh) 2013-12-11
BRPI0811589A2 (pt) 2014-10-29
US20090047268A1 (en) 2009-02-19
CA2687028A1 (en) 2009-02-26
PL2175875T3 (pl) 2017-04-28
HRP20161474T1 (hr) 2016-12-30
CL2008002390A1 (es) 2009-05-29
BRPI0811589B8 (pt) 2021-05-25
AU2008289549B2 (en) 2014-02-06
PE20090605A1 (es) 2009-05-16
MX2009012261A (es) 2010-03-15
RU2553343C2 (ru) 2015-06-10
CY1118222T1 (el) 2017-06-28
EP2175875A2 (en) 2010-04-21
US7537923B2 (en) 2009-05-26
AR117389A2 (es) 2021-08-04
EP2175875B1 (en) 2016-10-05
WO2009025760A3 (en) 2009-06-25
US20100278802A1 (en) 2010-11-04
RU2012134838A (ru) 2014-03-20
JP2010536759A (ja) 2010-12-02
BR122018072594B1 (pt) 2020-10-27
WO2009025760A2 (en) 2009-02-26
AR067972A1 (es) 2009-10-28
BRPI0811589B1 (pt) 2020-05-12
PT2175875T (pt) 2016-11-21
BR122018072594B8 (pt) 2021-07-27
US7790433B2 (en) 2010-09-07
CA2687028C (en) 2016-02-16
CN101803492A (zh) 2010-08-11
DK2175875T3 (en) 2016-11-21
TW200911283A (en) 2009-03-16
US20090263369A1 (en) 2009-10-22
US7560263B2 (en) 2009-07-14
RU2009141987A (ru) 2011-05-20
HUE029510T2 (hu) 2017-02-28
JP5584120B2 (ja) 2014-09-03
CN101803492B (zh) 2014-05-07
US20090047265A1 (en) 2009-02-19
HUE029510T4 (en) 2017-05-29
LT2175875T (lt) 2016-12-12
ES2602618T3 (es) 2017-02-21

Similar Documents

Publication Publication Date Title
HUE029510T2 (hu) Prokariota fenilalanin ammónia-liáz kompozíciók, valamint eljárás rák kezelésére az ezekbõl származó készítményekkel
HUS1900049I1 (hu) Prokarióta fenilalanin ammónia-liáz készítmények és azok alkalmazási eljárásai
IL257681A (en) Methods and compositions for the treatment of cancer
PL2155188T3 (pl) Sposoby i kompozycje do leczenia nawrotowego raka
PT2200431T (pt) Novos métodos e composições para o tratamento do cancro
IL257437B (en) Compositions of prokaryotic phenylalanine ammonia lyase variants and methods of using the compositions
PT2340042E (pt) Métodos e composições para o tratamento de cancro
PT2977456T (pt) Composições compreendendo hmw-maa e seus fragmentos para tratamento do cancro
EP2049151A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
PT2268292T (pt) Métodos e composições para o tratamento de cancro
EP2176406A4 (en) COMPOSITIONS AND METHOD FOR CANCER TREATMENT
IL243294A0 (en) Compounds and compositions for the treatment of cancer
HRP20130642T1 (en) Methods and compositions for treating cancers
IL204945A0 (en) Compositions and methods for inhibiting tumor progression
EP2137213A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER
EP1996211A4 (en) GALLIUM COMPOSITIONS FOR THE TREATMENT OF LIVER CANCER AND METHODS OF USE
EP1855662A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
EP2068629A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
HUE054409T2 (hu) Új kompozíciók és eljárások rák kezelésére
SI3067054T1 (sl) Novi sestavki in postopki za zdravljenje raka
GB2454875B (en) Parenteral composition for use in treatment of cancer and method of manufacture thereof
AU2007904940A0 (en) Methods and compositions for treating gynecological cancer
IL196361A0 (en) Combination methods of treating cancer
AU2007901628A0 (en) Methods and compositions for treating prostate cancer
HK1122507A (en) Methods and compositions for treating prostate cancer